Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
LiqTech International Q1 2026 Earnings Call - Gross Margin Expands as Commercial Pool and Marine Drive Repeatable Growth
LiqTech International reported a 10.4% year-over-year revenue decline to DKK 4.1 million in Q1 2026, but the headline miss masks a structural shift toward higher-margin, repeatable revenue streams. Gr...
- Revenue decreased 10.4% year-over-year to DKK 4.1 million, primarily due to the non-repeat of a significant water-for-energy delivery in Q1 2025.
- Gross margin expanded 280 basis points to 9.5%, with gross profit increasing despite lower revenue, driven by improved sales mix and better manufacturing utilization.
- Commercial pool revenue tripled to DKK 0.8 million, with a strong order book setting the stage for a record Q2 2026 quarter.
- +12 more takeaways
Kornit Digital Q1 2026 Earnings Call - Digital Shift Accelerates with Atlas MATRIX Launch and PrintFactory Acquisition
Kornit Digital delivered a strong Q1 2026, hitting the top end of revenue guidance at $48.5 million while expanding its Adjusted EBITDA loss to $2.8 million, a clear improvement from the prior year. T...
- Q1 2026 revenue hit $48.5 million, landing at the high end of guidance, with 4% year-over-year product growth and 7% services growth.
- AIC (All-Inclusive Click) revenue surged 103% year-over-year, ending the quarter with $27 million in Annual Recurring Revenue (ARR) and a 40% new customer mix.
- Trailing 12-month impressions grew 12% year-over-year, signaling strong system utilization and accelerating the shift from analog screen printing to digital production.
- +7 more takeaways
Enovis Q1 2026 Earnings Call - Strong Recon Growth and ARVIS Launch Offset Macro Headwinds
Enovis delivered a solid start to 2026 with 6% days-adjusted organic growth, driven by double-digit gains in U.S. extremities and a successful launch of the ARVIS shoulder system. The company navigate...
- Days-adjusted organic revenue growth reached 6%, with 8% in Recon and 3% in Prevention & Recovery, outpacing both segments' respective markets.
- U.S. Recon grew 8% organically, led by 10% growth in extremities, driven by the Augmented Reverse Glenoid System and double-digit shoulder gains.
- The ARVIS shoulder system launched successfully with early positive feedback, targeting competitive conversion and ASC penetration through flexible purchasing models.
- +7 more takeaways
Eos Energy Enterprises Q1 2026 Earnings Call - Frontier Power USA Launch and DawnOS Performance Breakthrough
Eos Energy Enterprises delivered $57 million in Q1 2026 revenue, a 445% year-over-year increase, driven by a 5.5x jump in production output. The company closed the quarter with $645 million in backlog...
- Eos Energy Enterprises reported Q1 2026 revenue of $57 million, up 445% year-over-year, with production output surging 5.5 times compared to the same quarter last year.
- The company announced Frontier Power USA, a new platform that merges Eos’s battery technology with project development, insurance-backed financing, and $150 million in equity from Cerberus and a pro-rata rights offering to existing shareholders.
- Eos’s backlog stands at $645 million and will increase with a 2 GWh capacity reservation agreement with Frontier Power USA, reflecting a $24 billion, 107 GWh commercial pipeline with 55% of opportunities at 8-hour-plus duration.
- +7 more takeaways
Everus Construction Group Q1 2026 Earnings Call - Record Backlog and Margin Expansion Fuel Raised Guidance
Everus Construction Group delivered a powerful start to 2026, reporting record Q1 revenues of $1.04 billion and a 44% surge in EBITDA. The company’s disciplined approach to project selection and contr...
- Q1 2026 revenues reached a record $1.04 billion, a 25% increase from the prior year period, driven by robust growth across both the E&M and T&D segments.
- EBITDA surged 44% to $88.9 million, with EBITDA margins expanding 110 basis points to 8.6%, reflecting strong project execution and favorable weather conditions.
- Backlog hit a record $3.68 billion, up 20% year-over-year, with the E&M segment backlog growing 22% and T&D backlog increasing 10%.
- +7 more takeaways
Abeona Therapeutics Q1 2026 Earnings Call - ZEVASKYN Launch Momentum Surges as PSMA CAR-T Pipeline Expansion Signals Strategic Pivot
Abeona Therapeutics delivered a pivotal first quarter for its flagship gene therapy ZEVASKYN, with revenue jumping to $8.7 million as commercial traction accelerates. The company treated five patients...
- ZEVASKYN revenue surged to $8.7 million in Q1 2026, up from $2.4 million in Q4 2025, driven by three commercial treatments and early market traction.
- Five patients have been treated with ZEVASKYN to date, with six additional patients expected to undergo biopsies this quarter, signaling accelerating commercial momentum.
- Abeona activated two new Qualified Treatment Centers (QTCs), bringing the total to six, including Children’s Hospital of Philadelphia and NewYork-Presbyterian/Columbia University.
- +7 more takeaways
Milestone Pharma Q1 2026 Earnings Call - CARDEMYST Launch Gains Traction as ReVeRA-301 AFib Trial Begins
Milestone Pharmaceuticals reported its first partial quarter of commercial sales for CARDEMYST (etripamil), generating $0.2 million in revenue against a $26.1 million net loss. The launch is showing e...
- CARDEMYST (etripamil) generated $0.2 million in product revenue in Q1 2026, marking the first partial quarter of commercial sales since launch.
- Approximately 600 total prescriptions were written through the end of April, with steady month-over-month growth from 100 scripts in February to 300 in April.
- Over 400 unique healthcare professionals prescribed CARDEMYST to approximately 560 unique patients, indicating broad early adoption across cardiology (50%) and electrophysiology (25%).
- +7 more takeaways
Altimmune Q1 2026 Earnings Call - Pemvidutide Phase III Trial Launch and $535M Balance Sheet Secure Runway to 2029
Altimmune has secured its financial footing with a $225 million oversubscribed public offering, bringing its cash balance to $535 million. This runway fully funds operations through the Phase III MASH...
- Completed an oversubscribed public offering in April 2026, raising $225 million in gross proceeds and boosting the cash balance to $535 million as of April 30, 2026.
- The current cash position fully funds Altimmune’s operations through the Phase III MASH 52-week data readout expected in 2029, eliminating near-term dilution risk.
- Initiation of the global Phase III PERFORMA trial in MASH is targeted for the second half of 2026, with final protocol alignment secured from both the FDA and EMA.
- +7 more takeaways
Flex LNG Q1 2026 Earnings Call - Geopolitical Shock Drives Record Spot Rates and Upgraded Guidance
Flex LNG delivered a quarter defined by operational discipline and a geopolitical windfall. Q1 revenues of $78 million (excluding EUAs) and adjusted net income of $16.9 million were bolstered by the s...
- Q1 2026 revenues reached $78 million excluding EUAs, with adjusted net income of $16.9 million ($0.31 EPS), driven by operational efficiency and favorable spot market conditions.
- Fleet average Time Charter Equivalent (TCE) stood at $65,700 per day, reflecting strong utilization despite seasonal softness and scheduled dry dockings.
- Contract coverage for 2026 is now 91%, with 54 years of minimum backlog and potential to reach 81 years if all charter options are exercised.
- +12 more takeaways
EOG Resources Q1 2026 Earnings Call - Capital Reallocation to Oil and Record Cash Returns
EOG Resources kicked off 2026 with a strong operational and financial performance, generating $1.8 billion in adjusted net income and $1.5 billion in free cash flow. The company successfully beat guid...
- EOG Resources delivered exceptional Q1 2026 results, generating $1.8 billion in adjusted net income and $1.5 billion in free cash flow.
- The company beat guidance on production volumes, total per-unit cash operating costs, and DD&A, demonstrating strong operational execution.
- EOG increased its full-year 2026 oil production guidance by 2,000 bbl/day and NGL guidance by 6,000 bbl/day by reallocating capital from gas to oil-weighted assets.
- +9 more takeaways